Advances in prevention and treatment of graft versus host disease

Bibliography

• BEATTY PG, HANSEN JA, THOMAS ED et al.: Marrow transplantation from HLA-matched unrelated donors for treatment of hematologic malignancies. Transplantation (1991) 51(2):443–447.
   PubMedGoogle Scholar
• MACKINNON S, HOWS JM, GOLDMAN JM et al.: Bone marrow transplantation for chronic myeloid leukaemia: the use of histocompatible unrelated volunteer donors. Exp. Heinatol (1990) 18(5):421–425.
   PubMedGoogle Scholar
• SIERRA J, RADICH J, HANSEN JA et al.: Marrow transplants from unrelated donors for treatment of Philadelphia chromosome-positive acute lymphoblastic leukaemia. Blood (1997) 90(4):1410–1414.
   PubMedGoogle Scholar
• MARTIN PJ, HANSEN JA, STORB R, THOMAS ED: Human marrow transplantation: an immunological perspective. Adv. Inonunol. (1987) 40:379–438.
   PubMed Web of Science ®Google Scholar
• OCHS LA, MILLER WJ, FILIPOVICH AH et al.: Predictive factors for chronic graft versus host disease after histocompatible sibling donor bone marrow transplantation. Bone Marrow Transplant. (1994) 13(4):455–460.
   PubMedGoogle Scholar
• PARKMAN R: Chronic graft versus host disease. Can: Opin. Heinatol (1998) 5:22–25.
   PubMedGoogle Scholar
• BENSINGER WI, BUCKNER CD, SHANNON-DORCY K et al.: Transplantation of allogeneic CD34+ peripheral blood stem cells in patients with advanced hematologic malignancy. Blood (1996) 88(11):4132–4138.
   PubMedGoogle Scholar
• MIFLIN G, RUSSELL NH, HUTCHINSON RM et al.: Allogeneic peripheral blood stem cell transplantation for hematological malignancies: an analysis of kinetics of engraftment and GVHD risk. Bone Marrow Transplant. (1997) 19(1):9–13.
   PubMedGoogle Scholar
• KLINGEMANN HG: Chronic graft versus host disease. In: A Guide to Blood and Marrow Transplantation. Deeg H-J, Klingemann H-G, Phillips GL, Van Zant G (Eds.) Springer-Verlag, Berlin (1999):183–198.
   Google Scholar
• RATANATHARATHORN V, AYASH L, LAZARUS HM, FU J, UBERTI JP: Chronic graft versus host disease: clinical manifestation and therapy. Bone Marrow Transplant. (2001) 28(2):121–129.
   PubMed Web of Science ®Google Scholar
• REICH-ZELIGER S, ZHAO Y, KRAUTHGAMER R, BACHAR- LUSTIG E, REISNER Y: Antithird party CD8+ CTLs as potent veto cells: coexpression of CD8 and FasL is a prerequisite. Innnunio, (2000) 13(4):507–515.
   Google Scholar
• LAN F, ZENG D, HUIE P, HIGGINS JP, STROBER S: Allogeneic bone marrow cells that facilitate complete chimerism and eliminate tumour cells express both CD8 and T cell antigen receptor-all Blood (2001) 97(11):3458–3465.
   Google Scholar
• YOUNG KJ, DUTEMPLE B, ZHANG Z, LEVY G, ZHANG L: CD4-CD8- regulatory T cells implicated in preventing graft versus host and promoting graft-versus-leukaemia responses. Transplant. Proc. (2001) 33(1-2):1762–1763.
   PubMedGoogle Scholar
• CHANG CC, CIUBOTARIU R, MANAVALAN JS et al.: Tolerisation of dendritic cells by Ts cells: the crucial role of inhibitory receptors ILT3 and ILT4. Nat. brununol (2002) 3(3):237–243.
   PubMedGoogle Scholar
• ••An original article on the molecularmechanisms of CD8 T cell-mediated suppression of antigen-presenting cells.
   Google Scholar
• HILL GR, COOKE KR, BRINSON YS, BUNGARD D, FERRARA JL: Pretransplant chemotherapy reduces inflammatory cytokine production and acute graft versus host disease after allogeneic bone marrow transplantation. Transplantation (1999) 67(11):1478–1480.
   PubMedGoogle Scholar
• HEIDT PJ, VOSSEN JM: Experimental and clinical gnotobiotics: influence of the microflora on graft versus host disease after allogeneic bone marrow transplantation. Med (1992) 23(3-4):161–173.
   Google Scholar
• HILL GR, CRAWFORD JM, COOKE KR, BRINSON YS, PAN L, FERRARA JL: Total body irradiation and acute graft versus host disease: the role of gastrointestinal damage and inflammatory cytokines. Blood (1997) 90(8):3204–3213.
   PubMed Web of Science ®Google Scholar
• MILLAN MT, SHIZURU JA, HOFFMANN P et al.: A non-myeloablative conditioning regimen followed by progenitor cell (CD34+) infusion after kidney transplantation can achieve mixed chimerism and immunosuppressive drug withdrawal. FASEB J. (2002) 16(5):A1030.
   Google Scholar
• •An abstract justifying the use of mixed chimerism to induce immune tolerance in humans.
   Google Scholar
• RUSSELL PS, CHASE CM, SYKES M, ITO H, SHAFFER J, COLVIN RB: Tolerance, mixed chimerism and chronic transplant arteriopathy. I Innnunol. (2001) 167(10):5731–5740.
   Google Scholar
• SYKES M, SPITZER TR: Non-myeloblative induction of mixed haematopoietic chimerism: application to transplantation tolerance and hematologic malignancies in experimental and clinical studies. Cancer Treat. Res. (2002) 110:79–99.
   PubMedGoogle Scholar
• •A review of experimental and clinical protocols for mixed chimerism.
   Google Scholar
• DEEG HJ: Graft versus host disease (GVHD). In: A Guide to Blood and Marrow Transplantation. Deeg H-J, Klingemann H-G, Phillips GL, Van Zant G (Eds) Springer-Verlag, Berlin (1999):127–141.
   Google Scholar
• •A thorough review of the irnmunopathophysiology and treatment of GVHD.
   Google Scholar
• JOHNSON BD, DROBYSKI WR, TRUITT RL: Delayed infusion of normal donor cells after MHC-matched bone marrow transplantation provides an antileukaemia reaction without graft versus host disease. Bone Marrow Transplant (1993) 11(4):329–336.
   PubMedGoogle Scholar
• KOLB HJ, SCHATTENBERG A, GOLDMAN JM et al.: Graft-versus-leukaemia effect of donor lymphocyte transfusions in marrow grafted patients. European group for blood and marrow transplantation working party chronic leukaemia. Blood (1995) 86(5):2041–2050.
   Google Scholar
• SLAVIN S, NAPARSTEK E, NAGLER A et al.: Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukaemia relapse after allogeneic bone marrow transplantation. Blood (1996) 87(6):2195–2204.
   PubMed Web of Science ®Google Scholar
• LEES, CHONG SY, LEE JW et al: Differencein the expression of Fas/Fas-ligand and the lymphocyte subset reconstitution according to the occurrence of acute GVHD. Bone Marrow Transplant. (1997) 20(10):883–888.
   PubMedGoogle Scholar
• DAS H, IMOTO S, MURAYAMA T et al.: Levels of soluble FasL and FasL gene expression during the development of graft versus host disease in DLT-treated patients. Br. J. Haeinatol (1999) 104(4):795–800.
   PubMed Web of Science ®Google Scholar
• KANDA Y, TANAKA Y, SHIRAKAWA K et al: Increased soluble Fas-ligand in sera of bone marrow transplant recipients with acute graft versus host disease. Bone Marrow Transplant. (1998) 22(8):751–754.
   PubMed Web of Science ®Google Scholar
• LIEM LM, VAN LOPIK T, VAN NIEUWENHUIJZE AE, VAN HOUWELINGEN HC, AARDEN L, GOULMY E: Soluble Fas levels in sera of bone marrow transplantation recipients are increased during acute graft versus host disease but not during infections. Blood (1998) 91(4):1464–1468.
   PubMedGoogle Scholar